21 Sep 2023
Inventiva and Hepalys Pharma, Inc.  announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
License out/inPhase 3Fast Track
21 Sep 2023
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada  for Generalized Myasthenia Gravis
Clinical ResultDrug ApprovalImmunotherapy
21 Sep 2023
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
Drug ApprovalBiosimilarNDAAccelerated Approval
21 Sep 2023
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
Phase 2
21 Sep 2023
Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials
Clinical StudyGene Therapy
21 Sep 2023
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer
Orphan DrugFast Track
20 Sep 2023
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
Phase 3License out/inPhase 1
20 Sep 2023
PHAXIAM Therapeutics extends its phage portfolio to Klebsiella pneumoniae, a new resistant and aggressive bacterial target
Qualified Infectious Disease Product
20 Sep 2023
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
Phase 3
20 Sep 2023
LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis
INDImmunotherapyPhase 1
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.